Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
about
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
P2860
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clinical pharmacokinetics and ...... SGLT2 inhibitor ipragliflozin.
@en
type
label
Clinical pharmacokinetics and ...... SGLT2 inhibitor ipragliflozin.
@en
prefLabel
Clinical pharmacokinetics and ...... SGLT2 inhibitor ipragliflozin.
@en
P2093
P2860
P1476
Clinical pharmacokinetics and ...... SGLT2 inhibitor ipragliflozin.
@en
P2093
Ikumi Nakajo
James Keirns
Ronald Smulders
Stefanie Leeflang
Takeshi Kadokura
Walter Krauwinkel
Wenhui Zhang
Yuta Taniuchi
P2860
P2888
P304
P356
10.1007/S40262-014-0180-Z
P577
2014-11-01T00:00:00Z
P6179
1051620129